Skip to main content

One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments

Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.